Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Formatting issues with Eisai's original rufinamide anti-epilepsy NDA could result in a more than two-month delay in approval